February 20, 2024
“Gilead Sciences has agreed to buy CymaBay Therapeutics for $4.3 billion, gaining access to an experimental liver disease treatment with blockbuster potential as the U.S. drugmaker looks beyond its older HIV drugs for growth. Shares of the Newark, California-based drug developer jumped 24.6%… Continue Reading…
January 6, 2021
“Esperion (ESPR)… Overall, Esperion has 6 recent reviews on record, with a breakdown of 5 Buys and 1 Hold to give the stock a Strong Buy rating from the analyst consensus. The shares, trading at $27.16, have an average price target… Continue Reading…
January 5, 2021
“Esperion (ESPR)… Overall, Esperion has 6 recent reviews on record, with a breakdown of 5 Buys and 1 Hold to give the stock a Strong Buy rating from the analyst consensus. The shares, trading at $27.16, have an average price target… Continue Reading…
September 15, 2020
“Gilead Sciences will acquire biotech company Immunomedics in a $21 billion deal that will expand Gilead’s availability of cancer treatments, the companies announced on Sunday. Shares of Immunomedics surged more than 100% in premarket trading Monday. The deal will provide Gilead access to the drug Trodelvy, a… Continue Reading…
Recent Comments